메뉴 건너뛰기




Volumn 66, Issue SUPPL. 3, 2007, Pages

Thoughts on health economics in rheumatoid arthritis

(1)  Kobelt, Gisela a  

a NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

EID: 35649010029     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.078964     Document Type: Conference Paper
Times cited : (21)

References (28)
  • 1
    • 33947610184 scopus 로고    scopus 로고
    • Health economic issues in Rheumatoid Arthritis
    • Kobelt G. Health economic issues in Rheumatoid Arthritis. Scand J Rheumatol 2006;35:415-25.
    • (2006) Scand J Rheumatol , vol.35 , pp. 415-425
    • Kobelt, G.1
  • 2
    • 18644386700 scopus 로고    scopus 로고
    • International variation in resource utilisation and treatment costs for rheumatoid arthritis. A systematic literature review
    • Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis. A systematic literature review. Pharmacoeconomics 2005;23:243-57.
    • (2005) Pharmacoeconomics , vol.23 , pp. 243-257
    • Rosery, H.1    Bergemann, R.2    Maxion-Bergemann, S.3
  • 3
    • 33747759417 scopus 로고    scopus 로고
    • Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany
    • Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;65:1175-83.
    • (2006) Ann Rheum Dis , vol.65 , pp. 1175-1183
    • Huscher, D.1    Merkesdal, S.2    Thiele, K.3    Zeidler, H.4    Schneider, M.5    Zink, A.6
  • 4
    • 35648964844 scopus 로고    scopus 로고
    • Kobelt G, Richard B, Peeters P, Sany J. Costs and quality of life of patients with RA in France. ACR abstract 2006; Bone Joint Spine. In press.
    • Kobelt G, Richard B, Peeters P, Sany J. Costs and quality of life of patients with RA in France. ACR abstract 2006; Bone Joint Spine. In press.
  • 5
    • 0037385979 scopus 로고    scopus 로고
    • Economic evaluation of programs or interventions in the management of rheumatoid arthritis: Defining a reference case
    • for the OMERACT group
    • Maetzel A, Tugwell P, Boers M, for the OMERACT group. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a reference case. J Rheumatol 2003;30:891-6.
    • (2003) J Rheumatol , vol.30 , pp. 891-896
    • Maetzel, A.1    Tugwell, P.2    Boers, M.3
  • 6
    • 0022633115 scopus 로고
    • Measurement of health state utilities for economic appraisal. A review
    • Torrance G. Measurement of health state utilities for economic appraisal. A review. J Health Econ 1986;5:1-30.
    • (1986) J Health Econ , vol.5 , pp. 1-30
    • Torrance, G.1
  • 9
    • 0025688231 scopus 로고
    • EuroQol: A new facility for the measurement of health-related quality of life
    • The EuroQol Group
    • The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
    • (1990) Health Policy , vol.16 , pp. 199-208
  • 12
    • 0033003967 scopus 로고    scopus 로고
    • Economic consequences of the progression of rheumatoid arthritis in Sweden
    • Kobelt G, Eberhardt K, Jönsson L, Jönsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
    • (1999) Arthritis Rheum , vol.42 , pp. 347-356
    • Kobelt, G.1    Eberhardt, K.2    Jönsson, L.3    Jönsson, B.4
  • 13
    • 0031134856 scopus 로고    scopus 로고
    • Measuring health-related quality of life in rheumatoid arthritis: Validity, responsiveness and reliability of EuroQol (EQ-5D)
    • Hurst N, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9.
    • (1997) Br J Rheumatol , vol.36 , pp. 551-559
    • Hurst, N.1    Kind, P.2    Ruta, D.3    Hunter, M.4    Stubbings, A.5
  • 14
    • 0036746102 scopus 로고    scopus 로고
    • Modelling the progression of rheumatoid arthritis, a two-country model to estimate costs and consequences of RA
    • Kobelt G, Jönsson L, Lindgren P, Young A, Eberhardt K. Modelling the progression of rheumatoid arthritis, a two-country model to estimate costs and consequences of RA. Arthritis Rheum 2002;46:2310-9.
    • (2002) Arthritis Rheum , vol.46 , pp. 2310-2319
    • Kobelt, G.1    Jönsson, L.2    Lindgren, P.3    Young, A.4    Eberhardt, K.5
  • 15
    • 24144476312 scopus 로고    scopus 로고
    • Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis
    • Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 2005;44:1169- 75.
    • (2005) Rheumatology (Oxford) , vol.44 , pp. 1169-1175
    • Kobelt, G.1    Lindgren, P.2    Lindroth, Y.3    Jacobson, L.4    Eberhardt, K.5
  • 16
    • 0347950999 scopus 로고    scopus 로고
    • TNF-inhibitors in the treatment of rheumatoid arthritis in clinical practice: Costs and outcomes in a follow-up study of patients with RA treated with etanercept or infliximab in southern Sweden
    • Kobelt G, Eberhardt K, Geborek P. TNF-inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow-up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10.
    • (2004) Ann Rheum Dis , vol.63 , pp. 4-10
    • Kobelt, G.1    Eberhardt, K.2    Geborek, P.3
  • 17
    • 33646559212 scopus 로고    scopus 로고
    • Hulsemann JL, Ruof J, Zeidler H, Mittendorf T. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'. Rheumatol Int 2005;26:704-11.
    • Hulsemann JL, Ruof J, Zeidler H, Mittendorf T. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'. Rheumatol Int 2005;26:704-11.
  • 18
    • 25644440064 scopus 로고    scopus 로고
    • Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference?
    • Drummond MF, Barbieri M, Wong JB. Analytic choices in economic models of treatments for rheumatoid arthritis: what makes a difference? Med Decis Making 2005;25:520-33.
    • (2005) Med Decis Making , vol.25 , pp. 520-533
    • Drummond, M.F.1    Barbieri, M.2    Wong, J.B.3
  • 19
    • 16344370052 scopus 로고    scopus 로고
    • An overview of economic evaluations for drugs used in rheumatoid arthritis: Focus on tumour necrosis factor-alpha antagonists
    • Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 2005;65:473-96.
    • (2005) Drugs , vol.65 , pp. 473-496
    • Bansback, N.J.1    Regier, D.A.2    Ara, R.3    Brennan, A.4    Shojania, K.5    Esdaile, J.M.6
  • 22
    • 0345294739 scopus 로고    scopus 로고
    • The cost-effectiveness of infliximab (Remicade(R)) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study
    • Kobelt G, Jönsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade(R)) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35.
    • (2003) Rheumatology , vol.42 , pp. 326-335
    • Kobelt, G.1    Jönsson, L.2    Young, A.3    Eberhardt, K.4
  • 23
    • 0036800337 scopus 로고    scopus 로고
    • Estimating the cost-effectiveness of infliximab for rheumatoid arthritis
    • Wong J, Singh G, Kavanough A. Estimating the cost-effectiveness of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
    • (2002) Am J Med , vol.113 , pp. 400-408
    • Wong, J.1    Singh, G.2    Kavanough, A.3
  • 24
    • 17344389740 scopus 로고    scopus 로고
    • The use of modelling to evaluate new drugs for patients with chronic conditions: The case of antibodies against tumour necrosis factor in rheumatoid arthritis
    • Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with chronic conditions: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technology Assessment 2004;8:1-91.
    • (2004) Health Technology Assessment , vol.8 , pp. 1-91
    • Barton, P.1    Jobanputra, P.2    Wilson, J.3    Bryan, S.4    Burls, A.5
  • 25
    • 0345832266 scopus 로고    scopus 로고
    • Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK
    • Brennan A, Bansback N, Reynolds A, Conway P. Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004;43:62-72.
    • (2004) Rheumatology , vol.43 , pp. 62-72
    • Brennan, A.1    Bansback, N.2    Reynolds, A.3    Conway, P.4
  • 26
    • 21344455325 scopus 로고    scopus 로고
    • Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden
    • Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995-1002.
    • (2005) Ann Rheum Dis , vol.64 , pp. 995-1002
    • Bansback, N.J.1    Brennan, A.2    Ghatnekar, O.3
  • 27
    • 23444460855 scopus 로고    scopus 로고
    • Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial
    • Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005;64:1174-9.
    • (2005) Ann Rheum Dis , vol.64 , pp. 1174-1179
    • Kobelt, G.1    Lindgren, P.2    Singh, A.3    Klareskog, L.4
  • 28
    • 34547839821 scopus 로고    scopus 로고
    • Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Registry
    • Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, et al. Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 2007;46:1345-54.
    • (2007) Rheumatology (Oxford) , vol.46 , pp. 1345-1354
    • Brennan, A.1    Bansback, N.2    Nixon, R.3    Madan, J.4    Harrison, M.5    Watson, K.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.